On Monday, Novo Nordisk A/S (NYSE:NVO) announced headline results from the REDEFINE 2 phase 3 trial in the global REDEFINE program.
REDEFINE 2 is a 68-week efficacy and safety trial investigating once-weekly subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to placebo.
The trial included 1,206 randomized people with obesity or overweight, type 2 diabetes, and a mean baseline body weight of 102 kg.
The REDEFINE 2 trial was based on a flexible protocol, allowing patients to modify their dosing throughout the trial.
Also Read: Weight Loss Drugs Soar While Global Obesity Rates Climb, To Hit 50% Of Adults By 2050 Says New Report
After 68 weeks, 61.9% of patients treated with CagriSema were on the highest dose.
When evaluating treatment effects, if all people adhered to treatment, people treated with CagriSema achieved a weight loss of 15.7% after 68 weeks compared to 3.1% with placebo.
A co-primary endpoint was a weight loss of 5% or more after 68 weeks, which was achieved by 89.7% of patients on CagriSema, compared to 30.3% by placebo.
When applying the treatment policy estimand, people treated with CagriSema achieved a superior weight loss of 13.7% compared to 3.4% with placebo.
In the trial, CagriSema appeared to have a safe and well-tolerated profile. The most common adverse events with CagriSema were gastrointestinal, and the vast majority were mild to moderate and diminished over time, consistent with the GLP-1 receptor agonist class.
In December, in the REDEFINE 1 Phase 3 trial, CagriSema achieved a weight loss of 22.7% after 68 weeks compared to a reduction of 11.8% with cagrilintide 2.4 mg, 16.1% with semaglutide 2.4 mg and 2.3% with placebo alone, below the Street expectations of 25%.
Novo Nordisk expects to file for the first regulatory approval of CagriSema in the first quarter of 2026.
The detailed results from REDEFINE 1 and REDEFINE 2 will be presented at a scientific conference in 2025.
Price Action: At the last check on Tuesday, NVO stock was up 0.49% at $79.35 during the premarket session.
Read Next:
Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market.
Get the latest stock analysis from Benzinga?
This article Novo Nordisk's Combo Drug CagriSema Shows 16% Weight Reduction In Second Phase 3 Trial originally appeared on Benzinga.com
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。